NK520 Clinical Trials

1 actively recruiting trial

▼ -1 trial since June 2026

Also known as: genetic modified NK cell

Pipeline

Early 1: 1

Top Sponsors

Base Therapeutics (Shanghai) Co., Ltd.1

Indications

Relapsed/Refractory Acute Myeloid Leukemia1
Cancer1

Other1 trial

Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.